CHM · ASX

Chimeric Therapeutics Limited (ASX:CHM)

AU$0.0045

 5.0E-4 (12.5%)
ASX:Live
01/07/2025 12:00:00 AM
HALO Ords GROWTH AUS Extreme Overbought Big Candle All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CHM Overview

CHM Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About CHM

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053

Description

Chimeric Therapeutics Ltd. is a clinical stage cell therapy company, which engages in the development and commercialization of cell therapies in oncology. Its products include NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company was founded by Paul A. Hopper in 2020 and is headquartered in Carlton South, Australia.

CHM Price Chart

Key Stats

Market Cap

AU$8.06M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.02

Trade Value (12mth)

AU$6,590.00

1 week

12.5%

1 month

12.5%

YTD

-32.5%

1 year

-75.13%

All time high

0.40

Key Fundamentals

EPS 3 yr Growth

-77.50%

EBITDA Margin

N/A

Operating Cashflow

-$8m

Free Cash Flow Return

-185.70%

ROIC

-308.20%

Interest Coverage

N/A

Quick Ratio

0.30

Other Data

Shares on Issue (Fully Dilluted)

1055m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CHM Announcements

Latest Announcements

Date Announcements

01 July 25

Professor Miles Prince appointed as Non-Executive Director

×

Professor Miles Prince appointed as Non-Executive Director

01 July 25

Change of Director's Interest Notice LR

×

Change of Director's Interest Notice LR

26 June 25

Notification of cessation of securities - CHM

×

Notification of cessation of securities - CHM

24 June 25

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

17 June 25

Translational data shows persistence of CHM CDH17

×

Translational data shows persistence of CHM CDH17

10 June 25

Chimeric receives $2.5 M advance on FY25 R&D tax incentive

×

Chimeric receives $2.5 M advance on FY25 R&D tax incentive

04 June 25

CHM CDH17 receives FDA Fast Track

×

CHM CDH17 receives FDA Fast Track

29 May 25

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

28 May 25

Change in substantial holding - PH

×

Change in substantial holding - PH

26 May 25

Prospectus

×

Prospectus

26 May 25

Letter to Shareholders

×

Letter to Shareholders

26 May 25

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

22 May 25

Presentation to investor webinar

×

Presentation to investor webinar

21 May 25

CHM CDH17 ADVANCES TO DOSE LEVEL 2

×

CHM CDH17 ADVANCES TO DOSE LEVEL 2

20 May 25

$6.6 million Placement to advance clinical trial pipeline

×

$6.6 million Placement to advance clinical trial pipeline

20 May 25

Proposed issue of securities - CHM

×

Proposed issue of securities - CHM

20 May 25

Proposed issue of securities - CHM

×

Proposed issue of securities - CHM

20 May 25

Investor webinar

×

Investor webinar

16 May 25

Trading Halt

×

Trading Halt

15 May 25

Pause in Trading

×

Pause in Trading

15 May 25

Trading Halt

×

Trading Halt

15 May 25

ADVENT-AML Phase 1B clinical trial update

×

ADVENT-AML Phase 1B clinical trial update

09 May 25

Application for quotation of securities - CHM

×

Application for quotation of securities - CHM

01 May 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

01 May 25

Change of Director's Interest Notice PH

×

Change of Director's Interest Notice PH

01 May 25

Change in substantial holding

×

Change in substantial holding

CHM Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.06 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.06 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 44.8 -35.4 69.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.04 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.0 -54.7 73.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -39.8 -99.1 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.06 0.01 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.9 -151.0 24.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 378 455 730 Lock Lock Lock
Basic m Lock Lock Lock Lock 378 455 730 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 14 29 20 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -12.1 -1.6 -4.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -14 -29 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.7 -109.4 30.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -15 -29 -21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.8 -102.3 29.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -16 -30 -16 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -4 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -16 -26 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.2 -63.0 51.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -16 -8 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 10 0 8 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -13 -16 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -48.6 -23.9 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 18 5 3 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 35 22 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -18 -5 -3 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 9 17 13 Lock Lock Lock
Equity $m Lock Lock Lock Lock 26 6 2 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 26 6 2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.3 -78.0 -56.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -45.6 -115.8 -82.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -61.8 -457.8 -507.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -57.3 -188.0 -509.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -62.5 -165.2 -308.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -51.7 -104.0 -185.7 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -21.3 -36.9 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.3 0.2 0.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -71.5 -94.9 -123.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.3 0.6 0.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.3 0.6 0.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.8 57.4 94.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -145.8 -111.1 -74.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -45.6 -115.8 -82.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 4.0 6.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -61.8 -457.8 -507.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -61.8 -457.8 -507.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,295.2 2,289.8 1,924.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,295.2 -2,289.8 -1,924.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CHM Shortsell

Frequently Asked Questions

The current share price of Chimeric Therapeutics Limited (CHM:ASX) is AU$0.0045.
The 52-week high share price for Chimeric Therapeutics Limited (CHM:ASX) is AU$0.02.
The 52-week low share price for Chimeric Therapeutics Limited (CHM:ASX)? is AU$0.00.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) has a franking level of 0.0%.
Chimeric Therapeutics Limited (CHM:ASX) is classified in the Healthcare.
The current P/E ratio for Chimeric Therapeutics Limited (CHM:ASX) is .
The current share price of Chimeric Therapeutics Limited (CHM:ASX) is AU$0.0045.
The 52-week high share price for Chimeric Therapeutics Limited (CHM:ASX) is AU$0.02.
The 52-week low share price for Chimeric Therapeutics Limited (CHM:ASX)? is AU$0.00.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.
Chimeric Therapeutics Limited (CHM:ASX) has a franking level of 0.0%.
Chimeric Therapeutics Limited (CHM:ASX) is classified in the Healthcare.
The current P/E ratio for Chimeric Therapeutics Limited (CHM:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.